Zuclopenthixol is not approved for marketing in the United States, by the U.S. Food and Drug Administration, but is available in other countries. Limited information indicates that maternal oral doses of up to 50 mg daily or depot injections of 72 mg every 2 weeks produce low levels in breastmilk and no detectable short-term adverse effects in the breastfed infants. No long-term data are available. One international guideline recommends that women taking zuclopenthixol not breastfeed.[1] However, a safety scoring system finds zuclopenthixol possible to use cautiously during breastfeeding.[2] Until more data are available, zuclopenthixol should be used with careful infant monitoring during breastfeeding.